Anti-Cancer Vaccines Designed with mRNA Tecnology
Defence Therapeutics Inc. announced today it is initiating a new research and development program designed to exploit the Accum technology in engineering messenger RNA (mRNA) vaccines targeting cancer.
Accum is designed for intracellular accumulation with the capability to deliver an increased drug delivery to the targeted cells.
"The use of mRNA vaccines .... has definitely sparked a major line of interest in the use of this technology for other diseases such as cancer. The success of these mRNA anti-cancer vaccines relies primarily on their ability to escape endosomes to reach the cytoplasm of the cell where the final protein product is generated," says Mr. Plouffe, the CEO of Defence Therapeutics, in a press release on October 31, 2022.
Defence and its scientific team see that the application of Accum makes perfect sense as this platform is specially designed to overcome one "global and limiting step" for any molecular biopharmaceutical: endosomal escape.
